Nvidia's $2B Infusion Eases Nebius' Funding, But Profitability and Control Hurdles Persist

What happened

Nebius Group has secured a $2 billion investment from Nvidia through a pre-funded warrant, providing immediate capital for its AI infrastructure buildout as reported in a recent article. This move aligns with the DeepValue master report's expectation of strategic financing, reinforcing access to growth capital but embedding dilution via approximately 21.1 million new shares. However, the investment fails to address Nebius' core financial weaknesses, including ongoing unprofitability and no expected free cash flow until 2029, as highlighted in both sources. Critical de-risking gates from the report—such as securing contract-secured debt tied to the Microsoft agreement and remediating material weaknesses in internal controls—remain unresolved, undermining confidence in capital efficiency. Execution risks, including power delivery delays at the Independence site and political opposition, continue to pose significant threats to the scaled capacity targets touted in the news.

Implication

Immediately, the $2 billion inflow bolsters liquidity but dilutes per-share value through the warrant issuance, increasing pressure on equity holders without improving near-term earnings. This financing does not substitute for the contract-secured debt from Microsoft that is critical for reducing equity dependency and enabling capital-efficient growth, as emphasized in the DeepValue report. Investors must still monitor the remediation of internal control weaknesses, which, if unresolved, could impair financial reporting reliability during the high-capex buildout phase. With Nebius' valuation already pricing rapid capacity delivery, the lack of profitability and persistent execution risks heighten downside vulnerability if milestones are missed. Therefore, the DeepValue 'WAIT' rating remains prudent, advising patience until clearer proofs of financeable growth and operational maturity emerge.

Thesis delta

The Nvidia investment confirms near-term funding access but does not shift the core investment thesis, which hinges on contract-secured debt disclosure and internal control remediation. These key catalysts remain unmet, and the investment's dilution effect may even exacerbate per-share value concerns if other financing gaps persist. Thus, the recommendation to wait for these de-risking events or a lower entry price stands unchanged.